PHASE 3 STUDY OF DARIDOREXANT SHOWS THAT 50 MG IMPROVED BOTH SLEEP AND DAYTIME FUNCTIONING COMPARED TO PLACEBO IN WOMEN DURING MENOPAUSAL TRANSITION AGE
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.